Human immunodeficiency virus type 1 virions composed of unprocessed Gag and Gag-Pol precursors are capable of reverse transcribing viral genomic RNA.

Por Kaplan, A H, Krogstad, P, Kempf, D J, Norbeck, D W, Swanstrom, R
Publicado em 1994

An Enhanced Model of Middle Cerebral Artery Occlusion in Nonhuman Primates Using an Endovascular Trapping Technique

Por Tong, F.C., Zhang, X., Kempf, D.J., Yepes, M.S., Connor-Stroud, F.R., Zola, S., Howell, L.
Publicado no AJNR Am J Neuroradiol (2015)

In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations.

Por Kageyama, S, Weinstein, J N, Shirasaka, T, Kempf, D J, Norbeck, D W, Plattner, J J, Erickson, J, Mitsuya, H
Publicado em 1992

Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor.

Por Markowitz, M, Mo, H, Kempf, D J, Norbeck, D W, Bhat, T N, Erickson, J W, Ho, D D
Publicado em 1995

Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles.

Por Kaplan, A H, Zack, J A, Knigge, M, Paul, D A, Kempf, D J, Norbeck, D W, Swanstrom, R
Publicado em 1993

Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protea...

Por Bilello, J A, Bilello, P A, Stellrecht, K, Leonard, J, Norbeck, D W, Kempf, D J, Robins, T, Drusano, G L
Publicado em 1996

Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor.

Por Ho, D D, Toyoshima, T, Mo, H, Kempf, D J, Norbeck, D, Chen, C M, Wideburg, N E, Burt, S K, Erickson, J W, Singh, M K
Publicado em 1994

Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease.

Por Kaplan, A H, Michael, S F, Wehbie, R S, Knigge, M F, Paul, D A, Everitt, L, Kempf, D J, Norbeck, D W, Erickson, J W, Swanstrom, R
Publicado em 1994

Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease.

Por Kempf, D J, Marsh, K C, Paul, D A, Knigge, M F, Norbeck, D W, Kohlbrenner, W E, Codacovi, L, Vasavanonda, S, Bryant, P, Wang, X C
Publicado em 1991

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.

Por Kempf, D J, Marsh, K C, Denissen, J F, McDonald, E, Vasavanonda, S, Flentge, C A, Green, B E, Fino, L, Park, C H, Kong, X P
Publicado em 1995

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

Por Kempf, D J, Marsh, K C, Kumar, G, Rodrigues, A D, Denissen, J F, McDonald, E, Kukulka, M J, Hsu, A, Granneman, G R, Baroldi, P A, Sun, E, Pizzuti, D, Plattner, J J, Norbeck, D W, Leonard, J M
Publicado em 1997